State of Texas Seizes Hodgkin's Girl from Her Parents

Child welfare officials have seized a 12-year-old Hodgkin's lymphoma patient from her parents because they were keeping her from radiation treatment that doctors say she needs. Last weekend, the state assumed custody of Katie, who has already undergone chemotherapy (the doctors want her to have radiation in addition to the chemo, the parents are questioning the need).



The parents, Michele and Edward Wernecke, believe that the doctors have not been forthright about treatment for their daughter, Katie, particularly concerning the side effects of radiation, said the Werneckes' lawyer, David Horne. Her mother was arrested on charges of interfering with child custody but was released Monday on $50,000 bond.



At a hearing on Wednesday, the Werneckes asked a juvenile court judge to bar the doctors, at M. D. Anderson Cancer Center in Houston, from providing radiation therapy for Katie until a hearing next week to determine whether she will stay in state custody. The judge, Carl Lewis, said he would rule on the request on Friday.



This case could have broad implications on who ultimately has control over patient treatment - doctors or patients & loved ones.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap